SOPH · Insider Trading
SOPHiA GENETICS SA Ordinary Shares
Every open-market purchase and sale reported by SOPH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-14 | Philippe Menu | Chief Medical Officer | Sell | −5,000 | −$36.30K |
| 2026-10-14 | Jurgi Camblong | Executive Chairman | Sell | −8,500 | −$61.67K |
| 2026-10-14 | Zhenyu Xu | Chief Scientific Officer | Sell | −4,000 | −$28.73K |
| 2026-10-07 | George Cardoza | Chief Financial Officer | Sell | −1,592 | −$12.90K |
| 2026-10-07 | Zhenyu Xu | Chief Scientific Officer | Sell | −7,394 | −$60.07K |
| 2026-10-07 | Jurgi Camblong | Executive Chairman | Sell | −40,172 | −$326.53K |
| 2026-10-07 | Daan Van Well | Chief Legal Officer | Sell | −6,168 | −$50.10K |
| 2026-10-07 | Manuela Valente | Chief People Officer | Sell | −4,240 | −$34.49K |
| 2026-10-07 | Kevin Puylaert | Chief Sales Officer | Sell | −216 | −$1.74K |
| 2026-10-07 | Abhimanyu Verma | Chief Technology Officer | Sell | −5,284 | −$42.93K |
| 2026-10-07 | Philippe Menu | Chief Medical Officer | Sell | −7,394 | −$60.10K |
| 2026-10-07 | Ross Muken | Chief Executive Officer | Sell | −9,838 | −$79.97K |
| 2026-09-22 | Ross Muken | Chief Executive Officer | Sell | −422 | −$3.52K |
| 2026-09-22 | George Cardoza | Chief Financial Officer | Sell | −774 | −$6.45K |
| 2026-09-16 | Zhenyu Xu | Chief Scientific Officer | Sell | −4,000 | −$31.54K |
| 2026-09-16 | Philippe Menu | Chief Medical Officer | Sell | −5,000 | −$39.42K |
| 2026-09-14 | Jurgi Camblong | Executive Chairman | Sell | −8,500 | −$65.12K |
| 2026-09-14 | Daan Van Well | Chief Legal Officer | Sell | −6,168 | −$47.09K |
| 2026-09-10 | Kathy L Hibbs | Director | Sell | −6,250 | −$50.82K |
| 2026-08-31 | Zhenyu Xu | Chief Scientific Officer | Sell | −10,000 | −$89.10K |
| 2026-08-26 | Abhimanyu Verma | Chief Technology Officer | Sell | −10,000 | −$85.00K |
| 2026-08-26 | Philippe Menu | Chief Medical Officer | Sell | −5,000 | −$43.40K |
| 2026-08-26 | Kathy L Hibbs | Director | Sell | −6,250 | −$54.23K |
| 2026-08-21 | Manuela Valente | Chief People Officer | MIXED | — | −$47.44K |
| 2026-08-21 | Zhenyu Xu | Chief Scientific Officer | Sell | −20,000 | −$163.48K |
| 2026-08-14 | Philippe Menu | Chief Medical Officer | Sell | −5,000 | −$37.58K |
| 2026-08-14 | Zhenyu Xu | Chief Scientific Officer | Sell | −4,000 | −$30.08K |
| 2026-08-10 | Abhimanyu Verma | Chief Technology Officer | Sell | −5,000 | −$38.00K |
| 2026-08-10 | Jurgi Camblong | Executive Chairman | Sell | −28,500 | −$209.21K |
| 2026-08-07 | Zhenyu Xu | Chief Scientific Officer | MIXED | −10,000 | −$112.12K |
| 2026-08-05 | Jurgi Camblong | Executive Chairman | Sell | −20,000 | −$138.41K |
| 2026-08-05 | Abhimanyu Verma | Chief Technology Officer | Sell | −5,000 | −$34.77K |
| 2026-08-05 | Zhenyu Xu | Chief Scientific Officer | Sell | −10,000 | −$69.17K |
| 2026-07-28 | Philippe Menu | Chief Medical Officer | Sell | −5,000 | −$28.31K |
| 2026-07-22 | Jurgi Camblong | Executive Chairman | MIXED | −39,800 | −$271.62K |
| 2026-07-14 | Jurgi Camblong | Executive Chairman | Sell | −8,500 | −$47.79K |
| 2026-07-14 | Zhenyu Xu | Chief Scientific Officer | Sell | −4,000 | −$22.82K |
| 2026-07-14 | Philippe Menu | Chief Medical Officer | Sell | −5,000 | −$28.50K |
| 2026-07-08 | Jurgi Camblong | Executive Chairman | Sell | −17,685 | −$93.33K |
| 2026-07-07 | Manuela Valente | Chief People Officer | Sell | −4,241 | −$21.43K |
| 2026-07-07 | Jurgi Camblong | Executive Chairman | Sell | −22,486 | −$118.16K |
| 2026-07-07 | Ross Muken | Chief Executive Officer | Sell | −9,838 | −$51.35K |
| 2026-07-07 | Abhimanyu Verma | Chief Technology Officer | Sell | −5,285 | −$26.96K |
| 2026-07-07 | Zhenyu Xu | Chief Scientific Officer | Sell | −7,393 | −$38.24K |
| 2026-07-07 | Philippe Menu | Chief Medical Officer | Sell | −7,393 | −$38.16K |
| 2026-07-07 | Kevin Puylaert | Chief Sales Officer | Sell | −216 | −$1.09K |
| 2026-07-07 | George Cardoza | Chief Financial Officer | Sell | −1,592 | −$8.42K |
| 2026-07-01 | Jurgi Camblong | Executive Chairman | MIXED | −20,200 | −$306.10K |
| 2026-06-29 | Jurgi Camblong | Chief Executive Officer | MIXED | −19,502 | −$197.22K |
| 2026-06-26 | Abhimanyu Verma | Chief Technology Officer | Sell | −6,944 | −$38.23K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jurgi Camblong | Executive Chairman | 3,387,150 | $25.47M |
| Ross Muken | Chief Executive Officer | 660,391 | $4.97M |
| Zhenyu Xu | Chief Scientific Officer | 541,493 | $4.07M |
| Vincent Ossipow | Director | 522,860 | $3.93M |
| Daan Van Well | Chief Legal Officer | 332,716 | $2.50M |
| Troy Cox | Director | 328,743 | $2.47M |
| George Cardoza | Chief Financial Officer | 306,726 | $2.31M |
| Didier Hirsch | Director | 240,220 | $1.81M |
| Jean-Michel Cossery | Director | 206,212 | $1.55M |
| Manuela Valente | Chief People Officer | 206,210 | $1.55M |
| Philippe Menu | Chief Medical Officer | 195,993 | $1.47M |
| Abhimanyu Verma | Chief Technology Officer | 166,887 | $1.25M |
| Kevin Puylaert | Chief Sales Officer | 147,732 | $1.11M |
| Kathy L Hibbs | Director | 96,992 | $729.38K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SOPH quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.